Verification of the effects of calcium channel blockers on the immune microenvironment of breast cancer

BMC Cancer

Table 4 Univariate and multivariate analysis with respect to OS in TNBC

Parameters	Univarite analysis			Multivariate analysis
Parameters	Hazard ratio	95% CI	p value	Hazard ratio	95% CI	p value
Age at opetation (yr)
≤ 55 vs > 55	0.581	0.182–1.603	0.302
Tumor size (mm)
≤ 50 vs > 50	2.366	0.661–6.800	0.168
Skin infiltration
Negative vs Positive	2.948	0.822–8.488	0.091	3.321	0.891–10.307	0.071
Lymph node status
Negative vs Positive	2.269	0.631–14.474	0.233
Ki67
≤ 15% vs > 15%	3.762	0.756–68.181	0.120
Objective response rate
Non-Responders vs Responders	0.090	0.032–0.244	< 0.001	0.143	0.045–0.430	0.001
Pathological response
Non-pCR vs pCR	0.074	0.004–0.365	< 0.001	0.143	0.008–0.799	0.024
TILs
Low vs High	0.411	0.140–1.109	0.079	0.903	0.288–2.654	0.855
Hypertension
No vs Yes	1.161	0.182–4.181	0.847
Multiple types of AHT
No vs Yes	0.928	0.051–4.609	0.942
Calcium channel blockers
No vs Yes	0.699	0.039–3.465	0.715
ACEi or ARBs
No vs Yes	1.161	0.064–5.759	0.887
Beta-blockers
No vs Yes	–	–	0.206
Diuretics
No vs Yes	4.138	0.228–20.631	0.258

OS Overall survival, TNBC triple-negative breast cancer, CI confidence intervals, pCR pathological complete response, TILs tumor- infiltrating lymphocytes, AHT antihypertensive drug, ACEi angiotensin-converting-enzyme inhibitors, ARBs angiotensin II receptor blockers

ISSN: 1471-2407